Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sichuan Univ. ATR kinase compound 5g
- Development stage
- Unknown
- Lead developer
- Sichuan University
01
Overview
Sichuan Univ. ATR kinase compound 5g: sourced facts only. name: "Among them, compound 5g exhibits an IC50 value of 0.007 μM against ATR kinase." [PMID:35245663]; target: "Among them, compound 5g exhibits an IC50 value of 0.007 μM against ATR kinase." [PMID:35245663]; developer: "Key Laboratory of Drug Targeting and Drug Delivery System of Ministry of Education, West China School of Pharmacy, Sichuan University, Sichuan 610041, China." [PMID:35245663]
Beyond the preview
Go deeper on Sichuan Univ. ATR kinase compound 5g.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sichuan Univ. ATR kinase compound 5g.